Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.
BACKGROUND AND AIMS:This was a safety and efficacy pharmacogenetic study of a previously performed randomized trial which compared the effectiveness of treatment of hepatitis C virus infection with pegylated interferon alpha (pegIFNα) 2a vs. 2b, both with ribavirin, for 48 weeks, in HCV-HIV coinfect...
Main Authors: | Francesc Vidal, Miguel López-Dupla, Montserrat Laguno, Sergi Veloso, Josep Mallolas, Javier Murillas, Carmen Cifuentes, Lluis Gallart, Teresa Auguet, Gloria Sampériz, Antoni Payeras, Pilar Hernandez, Mireia Arnedo, Josep Ma Gatell, Cristóbal Richart |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3487790?pdf=render |
Similar Items
-
Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
by: Autumn D Zuckerman, et al.
Published: (2019-01-01) -
Treatment of HBV–HCV coinfection
by: Rocío Torres Ibarra
Published: (2006-01-01) -
Treatment of HCV and HIV coinfection
by: J. Alberto Juárez Navarro
Published: (2006-01-01) -
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
by: Chih-Wei Tseng, et al.
Published: (2022-04-01) -
The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting.
by: Jamie P Morano, et al.
Published: (2013-01-01)